Skip to main content
. 2018 Apr 3;13(4):e0195401. doi: 10.1371/journal.pone.0195401

Fig 5. Effect of the combined treatment with Golgi disrupting agents and Actinomycin D or Vinblastine on the apoptosis of MDA-MB-231 cells.

Fig 5

(A) Cells were left untreated, or transfected to transiently express the HA-epitope-tagged ARF1 constitutively-activated mutant (ARF1) for 16 h. Untransfected cells were left untreated for further 12 h (Control), or treated 12 h either with 10 ng/ml Actinomycin D (ActD) or 25 nM Vinblastine (VLB). Transfected cells were left untreated for further 12 h (ARF1), or treated 12 h either with 10 ng/ml Actinomycin D (ARF1 + ActD) or 25 nM Vinblastine (ARF1 + VLB). (B) Cells were left untreated for 12 h (Control), or treated 12 h either with 5 μg/ml Brefeldin A (BFA), 10 ng/ml Actinomycin D (ActD) or 25 nM Vinblastine (VLB), or with BFA in conjunction either with ActD (BFA + ActD) or VLB (BFA + VLB). (C) Cells were left untreated for 12 h (Control), or treated 12 h either with 10 μM Golgicide A (GCA), 10 ng/ml Actinomycin D (ActD) or 25 nM Vinblastine (VLB), or with GCA in conjunction either with ActD (GCA + ActD) or VLB (GCA + VLB). (A-C) Graphs depict the quantification of the number of cells decorated with Alexa-488-conjugated Annexin V. Bar represents the mean ± standard deviation (n = 3). * P < 0.05; ** P < 0.01; *** P < 0.001; ns, not statistically significant.